title: Current state of knowledge of hepatic encephalopathy (Part V): clinical efficacy of L-ornithine-L-aspartate in the management of HE.
abstract: In cirrhotic patients with portosystemic encephalopathy, OA has confirmed its efficacy both in uncontrolled clinical trials and more recently in placebo-controlled double-blind studies in patients with manifest hepatic encephalopathy and hyperammonemia. OA improved performance in Psyhometric Tests as well as mental state gradation. The therapy had little side effects, increasing with higher intravenously administered dosages, and was well tolerated after oral and parenteral administration.
authors.affiliation: , Düsseldorf, Germany. kircheis@med.uni-dusseldorf.de.
authors.forename: Gerald
authors.initials: G
authors.lastname: Kircheis
mesh_terms: D000818:Animals; D004151:Dipeptides / Q000008:administration & dosage*; D019468:Disease Management; D004333:Drug Administration Routes; D007722:Health Knowledge, Attitudes, Practice; D006501:Hepatic Encephalopathy / Q000188:drug therapy* / Q000378:metabolism* / Q000523:psychology; D006801:Humans; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D016896:Treatment Outcome
chemical_list: D004151:Dipeptides; C002939:ornithylaspartate
keywords: Artificial liver support; Hepatic encephalopathy; Hyperammonemia; L-Ornithine L-Aspartate: treatment of hepatic encephalopathy